Functional gastrointestinal disorders in women with systemic lupus erythematosus: A case‐control study
Background Systemic lupus erythematosus (SLE) is an autoimmune disease with multisystemic involvement. Gastrointestinal (GI) manifestations are frequent but functional gastrointestinal disorders (FGIDs) have scarcely been studied in SLE. To determine the prevalence of FGIDs and their potential risk...
Gespeichert in:
| Veröffentlicht in: | Neurogastroenterology and motility 2019-11, Vol.31 (11), p.e13693-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 11 |
| container_start_page | e13693 |
| container_title | Neurogastroenterology and motility |
| container_volume | 31 |
| creator | García‐Carrasco, Mario Mendoza‐Pinto, Claudia Munguía‐Realpozo, Pamela Méndez‐Valderrabano, Fabiola Méndez Martínez, Socorro Etchegaray Morales, Ivet Montiel‐Jarquín, Álvaro López‐Colombo, Aurelio Schmulson, Max |
| description | Background
Systemic lupus erythematosus (SLE) is an autoimmune disease with multisystemic involvement. Gastrointestinal (GI) manifestations are frequent but functional gastrointestinal disorders (FGIDs) have scarcely been studied in SLE. To determine the prevalence of FGIDs and their potential risk factors in SLE female patients vs controls.
Methods
Systemic lupus erythematosus patients meeting the American College of Rheumatology (ACR) criteria and controls completed the Rome III questionnaire for FGIDs and a structured interview to assess sociodemographic, clinical, and treatment variables after excluding organic GI diseases. Logistic regression was used to determine risk factors (ie, alcohol drinking, medications) for FGIDs.
Key Results
Responders included 113 SLE patients and 122 age‐matched controls. The presence of at least one FGIDs was higher in SLE (73.4%) vs controls (54.1%), P = .003. The most frequent FGIDs in SLE patients were nausea and vomiting disorders (NVD), belching disorders, globus, anorectal pain, functional heartburn (FH), and functional bloating (FB). After adjustment for confounding variables, SLE was associated with NVD (OR: 7.1, 95% CI: 2.7‐19.1) globus (3.5, 1.3‐9.3), anorectal pain (3.4, 1.4‐8.4), and FH (2.5, 1.5‐4.4). The simultaneous presence of >1 FGID was more common in SLE patients than controls (69.8% vs 31.8%). Glucocorticoids (5.2, 1.3‐19.9) and non‐steroidal anti‐inflammatory drugs (NSAIDs; 3.0, 1.1‐8.0) were associated with any FGID in SLE patients while alcohol drinking with gallbladder/sphincter of Oddi disorders 7.4 (1.1‐47.3).
Conclusions and Inferences
Functional gastrointestinal disorders are more frequent in SLE patients compared with controls. Medication that may alter gastrointestinal homeostasis, such as glucocorticoids and NSAIDs, are potential risk factors for FGIDs in SLE.
In this cross‐sectional, observational study including 113 systemic lupus patients (SLE) patients and 112 age‐matched controls, Functional gastrointestinal disorders (FGIDs) were more frequent in SLE patients compared with controls. Medication that may alter gastrointestinal homeostasis, such as glucocorticoids and NSAIDs are potential risk factors for FGIDs in SLE. |
| doi_str_mv | 10.1111/nmo.13693 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2268310827</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2304831910</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3133-a6d8b18ba1b749018afc231a9636554a48c00087ae0f217706abf92a316e7dd33</originalsourceid><addsrcrecordid>eNp1kMtKxDAUhoMoXkYXvoAE3OiiTi69uhvEUUGdja5LmqZOpG3GnATpzkfwGX0SM1ZdCGaRE8LHx_l_hA4pOaPhTPvOnFGeFnwD7YaZRKzI2eb6nZCIFizZQXsAz4SQlMXpNtrhlGecFGQXLee-l06bXrT4SYCzRvdOgdPrj1qDsbWygHWPX02nwq3dEsMATnVa4tavPGBlB7dUnXAGPJzjGZYC1MfbuzR98LUYnK-HfbTViBbUwfecoMf55cPFdXS7uLq5mN1GMizFI5HWeUXzStAqiwtCc9FIxqko0pAriUWcyxAjz4QiDaNZRlJRNQUTnKYqq2vOJ-hk9K6sefEhSdlpkKptRa-Mh5KxNOeU5CwL6PEf9Nl4G4IHipM4YAUlgTodKWkNgFVNubK6E3YoKSnX9Zeh_vKr_sAefRt91an6l_zpOwDTEXjVrRr-N5X3d4tR-QncmZCa</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2304831910</pqid></control><display><type>article</type><title>Functional gastrointestinal disorders in women with systemic lupus erythematosus: A case‐control study</title><source>Access via Wiley Online Library</source><source>Wiley Online Library (Open Access Collection)</source><creator>García‐Carrasco, Mario ; Mendoza‐Pinto, Claudia ; Munguía‐Realpozo, Pamela ; Méndez‐Valderrabano, Fabiola ; Méndez Martínez, Socorro ; Etchegaray Morales, Ivet ; Montiel‐Jarquín, Álvaro ; López‐Colombo, Aurelio ; Schmulson, Max</creator><creatorcontrib>García‐Carrasco, Mario ; Mendoza‐Pinto, Claudia ; Munguía‐Realpozo, Pamela ; Méndez‐Valderrabano, Fabiola ; Méndez Martínez, Socorro ; Etchegaray Morales, Ivet ; Montiel‐Jarquín, Álvaro ; López‐Colombo, Aurelio ; Schmulson, Max</creatorcontrib><description>Background
Systemic lupus erythematosus (SLE) is an autoimmune disease with multisystemic involvement. Gastrointestinal (GI) manifestations are frequent but functional gastrointestinal disorders (FGIDs) have scarcely been studied in SLE. To determine the prevalence of FGIDs and their potential risk factors in SLE female patients vs controls.
Methods
Systemic lupus erythematosus patients meeting the American College of Rheumatology (ACR) criteria and controls completed the Rome III questionnaire for FGIDs and a structured interview to assess sociodemographic, clinical, and treatment variables after excluding organic GI diseases. Logistic regression was used to determine risk factors (ie, alcohol drinking, medications) for FGIDs.
Key Results
Responders included 113 SLE patients and 122 age‐matched controls. The presence of at least one FGIDs was higher in SLE (73.4%) vs controls (54.1%), P = .003. The most frequent FGIDs in SLE patients were nausea and vomiting disorders (NVD), belching disorders, globus, anorectal pain, functional heartburn (FH), and functional bloating (FB). After adjustment for confounding variables, SLE was associated with NVD (OR: 7.1, 95% CI: 2.7‐19.1) globus (3.5, 1.3‐9.3), anorectal pain (3.4, 1.4‐8.4), and FH (2.5, 1.5‐4.4). The simultaneous presence of >1 FGID was more common in SLE patients than controls (69.8% vs 31.8%). Glucocorticoids (5.2, 1.3‐19.9) and non‐steroidal anti‐inflammatory drugs (NSAIDs; 3.0, 1.1‐8.0) were associated with any FGID in SLE patients while alcohol drinking with gallbladder/sphincter of Oddi disorders 7.4 (1.1‐47.3).
Conclusions and Inferences
Functional gastrointestinal disorders are more frequent in SLE patients compared with controls. Medication that may alter gastrointestinal homeostasis, such as glucocorticoids and NSAIDs, are potential risk factors for FGIDs in SLE.
In this cross‐sectional, observational study including 113 systemic lupus patients (SLE) patients and 112 age‐matched controls, Functional gastrointestinal disorders (FGIDs) were more frequent in SLE patients compared with controls. Medication that may alter gastrointestinal homeostasis, such as glucocorticoids and NSAIDs are potential risk factors for FGIDs in SLE.</description><identifier>ISSN: 1350-1925</identifier><identifier>EISSN: 1365-2982</identifier><identifier>DOI: 10.1111/nmo.13693</identifier><identifier>PMID: 31373090</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Alcohol ; Anorectal ; Autoimmune diseases ; Drinking behavior ; functional gastrointestinal disorders ; Gallbladder ; Gastrointestinal diseases ; globus ; Glucocorticoids ; Homeostasis ; Inflammation ; Lupus ; Nausea ; nausea and vomiting ; Nonsteroidal anti-inflammatory drugs ; NSAIDs ; Pain ; Patients ; Rheumatology ; Risk factors ; Sphincter ; Systemic lupus erythematosus ; Vomiting</subject><ispartof>Neurogastroenterology and motility, 2019-11, Vol.31 (11), p.e13693-n/a</ispartof><rights>2019 John Wiley & Sons Ltd</rights><rights>2019 John Wiley & Sons Ltd.</rights><rights>Copyright © 2019 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3133-a6d8b18ba1b749018afc231a9636554a48c00087ae0f217706abf92a316e7dd33</cites><orcidid>0000-0003-0531-9611 ; 0000-0001-7463-0580 ; 0000-0003-1696-9871 ; 0000-0002-5101-7705 ; 0000-0002-8440-8542 ; 0000-0002-2855-6161</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fnmo.13693$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fnmo.13693$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31373090$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>García‐Carrasco, Mario</creatorcontrib><creatorcontrib>Mendoza‐Pinto, Claudia</creatorcontrib><creatorcontrib>Munguía‐Realpozo, Pamela</creatorcontrib><creatorcontrib>Méndez‐Valderrabano, Fabiola</creatorcontrib><creatorcontrib>Méndez Martínez, Socorro</creatorcontrib><creatorcontrib>Etchegaray Morales, Ivet</creatorcontrib><creatorcontrib>Montiel‐Jarquín, Álvaro</creatorcontrib><creatorcontrib>López‐Colombo, Aurelio</creatorcontrib><creatorcontrib>Schmulson, Max</creatorcontrib><title>Functional gastrointestinal disorders in women with systemic lupus erythematosus: A case‐control study</title><title>Neurogastroenterology and motility</title><addtitle>Neurogastroenterol Motil</addtitle><description>Background
Systemic lupus erythematosus (SLE) is an autoimmune disease with multisystemic involvement. Gastrointestinal (GI) manifestations are frequent but functional gastrointestinal disorders (FGIDs) have scarcely been studied in SLE. To determine the prevalence of FGIDs and their potential risk factors in SLE female patients vs controls.
Methods
Systemic lupus erythematosus patients meeting the American College of Rheumatology (ACR) criteria and controls completed the Rome III questionnaire for FGIDs and a structured interview to assess sociodemographic, clinical, and treatment variables after excluding organic GI diseases. Logistic regression was used to determine risk factors (ie, alcohol drinking, medications) for FGIDs.
Key Results
Responders included 113 SLE patients and 122 age‐matched controls. The presence of at least one FGIDs was higher in SLE (73.4%) vs controls (54.1%), P = .003. The most frequent FGIDs in SLE patients were nausea and vomiting disorders (NVD), belching disorders, globus, anorectal pain, functional heartburn (FH), and functional bloating (FB). After adjustment for confounding variables, SLE was associated with NVD (OR: 7.1, 95% CI: 2.7‐19.1) globus (3.5, 1.3‐9.3), anorectal pain (3.4, 1.4‐8.4), and FH (2.5, 1.5‐4.4). The simultaneous presence of >1 FGID was more common in SLE patients than controls (69.8% vs 31.8%). Glucocorticoids (5.2, 1.3‐19.9) and non‐steroidal anti‐inflammatory drugs (NSAIDs; 3.0, 1.1‐8.0) were associated with any FGID in SLE patients while alcohol drinking with gallbladder/sphincter of Oddi disorders 7.4 (1.1‐47.3).
Conclusions and Inferences
Functional gastrointestinal disorders are more frequent in SLE patients compared with controls. Medication that may alter gastrointestinal homeostasis, such as glucocorticoids and NSAIDs, are potential risk factors for FGIDs in SLE.
In this cross‐sectional, observational study including 113 systemic lupus patients (SLE) patients and 112 age‐matched controls, Functional gastrointestinal disorders (FGIDs) were more frequent in SLE patients compared with controls. Medication that may alter gastrointestinal homeostasis, such as glucocorticoids and NSAIDs are potential risk factors for FGIDs in SLE.</description><subject>Alcohol</subject><subject>Anorectal</subject><subject>Autoimmune diseases</subject><subject>Drinking behavior</subject><subject>functional gastrointestinal disorders</subject><subject>Gallbladder</subject><subject>Gastrointestinal diseases</subject><subject>globus</subject><subject>Glucocorticoids</subject><subject>Homeostasis</subject><subject>Inflammation</subject><subject>Lupus</subject><subject>Nausea</subject><subject>nausea and vomiting</subject><subject>Nonsteroidal anti-inflammatory drugs</subject><subject>NSAIDs</subject><subject>Pain</subject><subject>Patients</subject><subject>Rheumatology</subject><subject>Risk factors</subject><subject>Sphincter</subject><subject>Systemic lupus erythematosus</subject><subject>Vomiting</subject><issn>1350-1925</issn><issn>1365-2982</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp1kMtKxDAUhoMoXkYXvoAE3OiiTi69uhvEUUGdja5LmqZOpG3GnATpzkfwGX0SM1ZdCGaRE8LHx_l_hA4pOaPhTPvOnFGeFnwD7YaZRKzI2eb6nZCIFizZQXsAz4SQlMXpNtrhlGecFGQXLee-l06bXrT4SYCzRvdOgdPrj1qDsbWygHWPX02nwq3dEsMATnVa4tavPGBlB7dUnXAGPJzjGZYC1MfbuzR98LUYnK-HfbTViBbUwfecoMf55cPFdXS7uLq5mN1GMizFI5HWeUXzStAqiwtCc9FIxqko0pAriUWcyxAjz4QiDaNZRlJRNQUTnKYqq2vOJ-hk9K6sefEhSdlpkKptRa-Mh5KxNOeU5CwL6PEf9Nl4G4IHipM4YAUlgTodKWkNgFVNubK6E3YoKSnX9Zeh_vKr_sAefRt91an6l_zpOwDTEXjVrRr-N5X3d4tR-QncmZCa</recordid><startdate>201911</startdate><enddate>201911</enddate><creator>García‐Carrasco, Mario</creator><creator>Mendoza‐Pinto, Claudia</creator><creator>Munguía‐Realpozo, Pamela</creator><creator>Méndez‐Valderrabano, Fabiola</creator><creator>Méndez Martínez, Socorro</creator><creator>Etchegaray Morales, Ivet</creator><creator>Montiel‐Jarquín, Álvaro</creator><creator>López‐Colombo, Aurelio</creator><creator>Schmulson, Max</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0531-9611</orcidid><orcidid>https://orcid.org/0000-0001-7463-0580</orcidid><orcidid>https://orcid.org/0000-0003-1696-9871</orcidid><orcidid>https://orcid.org/0000-0002-5101-7705</orcidid><orcidid>https://orcid.org/0000-0002-8440-8542</orcidid><orcidid>https://orcid.org/0000-0002-2855-6161</orcidid></search><sort><creationdate>201911</creationdate><title>Functional gastrointestinal disorders in women with systemic lupus erythematosus: A case‐control study</title><author>García‐Carrasco, Mario ; Mendoza‐Pinto, Claudia ; Munguía‐Realpozo, Pamela ; Méndez‐Valderrabano, Fabiola ; Méndez Martínez, Socorro ; Etchegaray Morales, Ivet ; Montiel‐Jarquín, Álvaro ; López‐Colombo, Aurelio ; Schmulson, Max</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3133-a6d8b18ba1b749018afc231a9636554a48c00087ae0f217706abf92a316e7dd33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Alcohol</topic><topic>Anorectal</topic><topic>Autoimmune diseases</topic><topic>Drinking behavior</topic><topic>functional gastrointestinal disorders</topic><topic>Gallbladder</topic><topic>Gastrointestinal diseases</topic><topic>globus</topic><topic>Glucocorticoids</topic><topic>Homeostasis</topic><topic>Inflammation</topic><topic>Lupus</topic><topic>Nausea</topic><topic>nausea and vomiting</topic><topic>Nonsteroidal anti-inflammatory drugs</topic><topic>NSAIDs</topic><topic>Pain</topic><topic>Patients</topic><topic>Rheumatology</topic><topic>Risk factors</topic><topic>Sphincter</topic><topic>Systemic lupus erythematosus</topic><topic>Vomiting</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>García‐Carrasco, Mario</creatorcontrib><creatorcontrib>Mendoza‐Pinto, Claudia</creatorcontrib><creatorcontrib>Munguía‐Realpozo, Pamela</creatorcontrib><creatorcontrib>Méndez‐Valderrabano, Fabiola</creatorcontrib><creatorcontrib>Méndez Martínez, Socorro</creatorcontrib><creatorcontrib>Etchegaray Morales, Ivet</creatorcontrib><creatorcontrib>Montiel‐Jarquín, Álvaro</creatorcontrib><creatorcontrib>López‐Colombo, Aurelio</creatorcontrib><creatorcontrib>Schmulson, Max</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Neurogastroenterology and motility</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>García‐Carrasco, Mario</au><au>Mendoza‐Pinto, Claudia</au><au>Munguía‐Realpozo, Pamela</au><au>Méndez‐Valderrabano, Fabiola</au><au>Méndez Martínez, Socorro</au><au>Etchegaray Morales, Ivet</au><au>Montiel‐Jarquín, Álvaro</au><au>López‐Colombo, Aurelio</au><au>Schmulson, Max</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Functional gastrointestinal disorders in women with systemic lupus erythematosus: A case‐control study</atitle><jtitle>Neurogastroenterology and motility</jtitle><addtitle>Neurogastroenterol Motil</addtitle><date>2019-11</date><risdate>2019</risdate><volume>31</volume><issue>11</issue><spage>e13693</spage><epage>n/a</epage><pages>e13693-n/a</pages><issn>1350-1925</issn><eissn>1365-2982</eissn><abstract>Background
Systemic lupus erythematosus (SLE) is an autoimmune disease with multisystemic involvement. Gastrointestinal (GI) manifestations are frequent but functional gastrointestinal disorders (FGIDs) have scarcely been studied in SLE. To determine the prevalence of FGIDs and their potential risk factors in SLE female patients vs controls.
Methods
Systemic lupus erythematosus patients meeting the American College of Rheumatology (ACR) criteria and controls completed the Rome III questionnaire for FGIDs and a structured interview to assess sociodemographic, clinical, and treatment variables after excluding organic GI diseases. Logistic regression was used to determine risk factors (ie, alcohol drinking, medications) for FGIDs.
Key Results
Responders included 113 SLE patients and 122 age‐matched controls. The presence of at least one FGIDs was higher in SLE (73.4%) vs controls (54.1%), P = .003. The most frequent FGIDs in SLE patients were nausea and vomiting disorders (NVD), belching disorders, globus, anorectal pain, functional heartburn (FH), and functional bloating (FB). After adjustment for confounding variables, SLE was associated with NVD (OR: 7.1, 95% CI: 2.7‐19.1) globus (3.5, 1.3‐9.3), anorectal pain (3.4, 1.4‐8.4), and FH (2.5, 1.5‐4.4). The simultaneous presence of >1 FGID was more common in SLE patients than controls (69.8% vs 31.8%). Glucocorticoids (5.2, 1.3‐19.9) and non‐steroidal anti‐inflammatory drugs (NSAIDs; 3.0, 1.1‐8.0) were associated with any FGID in SLE patients while alcohol drinking with gallbladder/sphincter of Oddi disorders 7.4 (1.1‐47.3).
Conclusions and Inferences
Functional gastrointestinal disorders are more frequent in SLE patients compared with controls. Medication that may alter gastrointestinal homeostasis, such as glucocorticoids and NSAIDs, are potential risk factors for FGIDs in SLE.
In this cross‐sectional, observational study including 113 systemic lupus patients (SLE) patients and 112 age‐matched controls, Functional gastrointestinal disorders (FGIDs) were more frequent in SLE patients compared with controls. Medication that may alter gastrointestinal homeostasis, such as glucocorticoids and NSAIDs are potential risk factors for FGIDs in SLE.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>31373090</pmid><doi>10.1111/nmo.13693</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-0531-9611</orcidid><orcidid>https://orcid.org/0000-0001-7463-0580</orcidid><orcidid>https://orcid.org/0000-0003-1696-9871</orcidid><orcidid>https://orcid.org/0000-0002-5101-7705</orcidid><orcidid>https://orcid.org/0000-0002-8440-8542</orcidid><orcidid>https://orcid.org/0000-0002-2855-6161</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1350-1925 |
| ispartof | Neurogastroenterology and motility, 2019-11, Vol.31 (11), p.e13693-n/a |
| issn | 1350-1925 1365-2982 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2268310827 |
| source | Access via Wiley Online Library; Wiley Online Library (Open Access Collection) |
| subjects | Alcohol Anorectal Autoimmune diseases Drinking behavior functional gastrointestinal disorders Gallbladder Gastrointestinal diseases globus Glucocorticoids Homeostasis Inflammation Lupus Nausea nausea and vomiting Nonsteroidal anti-inflammatory drugs NSAIDs Pain Patients Rheumatology Risk factors Sphincter Systemic lupus erythematosus Vomiting |
| title | Functional gastrointestinal disorders in women with systemic lupus erythematosus: A case‐control study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T12%3A29%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Functional%20gastrointestinal%20disorders%20in%20women%20with%20systemic%20lupus%20erythematosus:%20A%20case%E2%80%90control%20study&rft.jtitle=Neurogastroenterology%20and%20motility&rft.au=Garc%C3%ADa%E2%80%90Carrasco,%20Mario&rft.date=2019-11&rft.volume=31&rft.issue=11&rft.spage=e13693&rft.epage=n/a&rft.pages=e13693-n/a&rft.issn=1350-1925&rft.eissn=1365-2982&rft_id=info:doi/10.1111/nmo.13693&rft_dat=%3Cproquest_cross%3E2304831910%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2304831910&rft_id=info:pmid/31373090&rfr_iscdi=true |